Alterations in glycosaminoglycan biosynthesis associated with the Ehlers-Danlos syndromes

  • Delfien Syx
    Department of Biomolecular Medicine, Center for Medical Genetics, Ghent University, Ghent, Belgium
  • Sarah Delbaere
    Department of Biomolecular Medicine, Center for Medical Genetics, Ghent University, Ghent, Belgium
  • Catherine Bui
    CNRS IMoPA, Université de Lorraine, Nancy, France
  • Adelbert De Clercq
    Department of Biomolecular Medicine, Center for Medical Genetics, Ghent University, Ghent, Belgium
  • Göran Larson
    Department of Laboratory Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
  • Shuji Mizumoto
    Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Nagoya, Japan
  • Tomoki Kosho
    Center for Medical Genetics, Shinshu University Hospital, Matsumoto, Japan
  • Sylvie Fournel-Gigleux
    CNRS IMoPA, Université de Lorraine, Nancy, France
  • Fransiska Malfait
    Department of Biomolecular Medicine, Center for Medical Genetics, Ghent University, Ghent, Belgium

説明

<jats:p> Proteoglycans consist of a core protein substituted with one or more glycosaminoglycan (GAG) chains and execute versatile functions during many physiological and pathological processes. The biosynthesis of GAG chains is a complex process that depends on the concerted action of a variety of enzymes. Central to the biosynthesis of heparan sulfate (HS) and chondroitin sulfate/dermatan sulfate (CS/DS) GAG chains is the formation of a tetrasaccharide linker region followed by biosynthesis of HS or CS/DS-specific repeating disaccharide units, which then undergo modifications and epimerization. The importance of these biosynthetic enzymes is illustrated by several severe pleiotropic disorders that arise upon their deficiency. The Ehlers-Danlos syndromes (EDS) constitute a special group among these disorders. Although most EDS types are caused by defects in fibrillar types I, III, or V collagen, or their modifying enzymes, a few rare EDS types have recently been linked to defects in GAG biosynthesis. Spondylodysplastic EDS (spEDS) is caused by defective formation of the tetrasaccharide linker region, either due to β4GalT7 or β3GalT6 deficiency, whereas musculocontractural EDS (mcEDS) results from deficiency of D4ST1 or DS-epi1, impairing DS formation. This narrative review highlights the consequences of GAG deficiency in these specific EDS types, summarizes the associated phenotypic features and the molecular spectrum of reported pathogenic variants, and defines the current knowledge on the underlying pathophysiological mechanisms based on studies in patient-derived material, in vitro analyses, and animal models. </jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ